NEJM: Real-world research data of Kexing inactivated vaccines are released for the first time!

On July 7, the "New England Journal of Medicine" NEJM announced the real-world research data of Coxing's new crown vaccine (CoronaVac) in Chile.
This is the first time that the real world of Coxing's inactivated new crown vaccine has been published so far.
World research results
.

 The results of the study show that in the real world, Coxing's new crown vaccine effectively prevents Covid-19, including serious illness and death.
This finding is consistent with the results of the vaccine's Phase 2 trial
.

 DOI: 10.
1056/NEJMoa2107715 The study will be conducted from February 2 to May 1, 2021 (February 2, 2021, Chile started to use Coxing inactivated vaccine for mass vaccination, and priority is given to the elderly for vaccination), A prospective observation cohort was used at the national level.
The study cohort included participants aged 16 years or older, with approximately 10.
2 million people
.

 The researchers divided the participants into three groups: unvaccinated, partially immunized (≥14 days after the first dose of vaccine), and fully immunized (≥14 days after the second dose of vaccine)
.

The researchers used four main results to estimate the effectiveness of the vaccine: confirmed Covid-19, hospitalized due to Covid-19, admitted to the ICU due to Covid-19, and died due to Covid-19
.

It aims to evaluate the effectiveness of Kexing's inactivated Covid-19 vaccine in the real world
.

 The results of the study found that for people who received two doses of the vaccine, the estimated value of protection against the onset of Covid-19 was 65.
9%, the protection against hospitalization due to Covid-19 was 87.
5%, and the protection against admission to the intensive care unit due to Covid-19 was estimated to be 65.
9%.
The effectiveness is 90.
3%, while the protective effectiveness of preventing Covid-19-related deaths is 86.
3%
.

However, for partially immunized people (14 to 28 days after the first dose of vaccine), the estimated value of protection against Covid-19 is only 15.
5%, and the protection against hospitalization, admission to intensive care unit, and death due to Covid-19 are respectively 37.
4%, 44.
7% and 45.
7%
.

 According to the immune status, the effectiveness of Kexing's new crown vaccine in the prevention of Covid-19 in the entire study cohort.
It is worth noting that the vaccine is still very effective in preventing the new crown in people 60 years of age or older
.

In the subgroup of fully immunized persons 60 years of age or older, the effectiveness of preventing Covid-19 was 66.
6%, the effectiveness of preventing hospitalization due to Covid-19 was 85.
3%, and the effectiveness of preventing admission to the intensive care unit due to Covid-19 was 89.
2 %, and the effectiveness of protection against Covid-19-related deaths reached 86.
5%
.

 According to the immunization status, the effectiveness of Kexing's new crown vaccine in preventing Covid-19 in participants 60 years of age or older.
In the article, the study author pointed out that the vaccine's effectiveness (65.
9%) shown in the study is lower than that announced on Kexing's official website The results of the Phase 3 trial in Turkey (91.
3% vaccine effectiveness; 95% CI, 71.
3 to 97.
3) may be due to the small sample size of the Phase 3 clinical trial in Turkey, with only 1322 participants.
In addition, in this Chile In the study, priority is given to the elderly for vaccination, so the elderly have a very high vaccination rate
.

 In general, the results of the study show that Kexing's new crown inactivated vaccine is highly effective against serious diseases, hospitalizations and deaths, marking that the real-world effectiveness data of China's inactivated new crown vaccine has been internationally recognized
.

 Author | Jessica Editor | Jessica View the latest journal information, submission experience, click to read the original text